Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
The initiative will focus on advocating for cleaner air
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
For the treatment of Superficial Femoral Artery
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
Subscribe To Our Newsletter & Stay Updated
